Opinion|Videos|March 4, 2024
Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Daraxonrasib in Pancreatic Cancer
2
Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL
3
SERENA-4 Misses Primary PFS End Point With Camizestrant Plus Palbociclib in First-Line ER+ Advanced Breast Cancer
4
Anselamimab Misses Overall Primary End Point but Reduces Mortality in Kappa AL Amyloidosis
5